- $2.25m
- -$3.19m
- $0.07m
Brief: Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study
Brief: Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer’S Drug
Brief: Silo Pharma Achieves Key Milestone With First Dosing In IND-Enabling GLP Study For SPC-15 As A Groundbreaking PTSD Treatment
Brief: Silo Pharma Expands Intellectual Property Portfolio With Provisional Patent Filing For Innovative SPC-15 Combination Treatment
Brief: Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, And Tolerability Study Of SP-26 For Chronic Pain And Fibromyalgia
Brief: Silo Pharma Awarded US Patent For PTSD Treatment, Prepares For SPC-15 Clinical Trial
Brief: Silo Pharma Says IND Submission For Intranasal SPC-15 Treatment Expected In 2025
Brief: Silo Pharma Initiates Pharmacokinetic And Tolerability Study For Sp-26 Targeting Chronic Pain And Fibromyalgia
U.S. STOCKS ON THE MOVE-WW Grainger, Silo Pharma, Prologis
U.S. STOCKS ON THE MOVE-Prologis, Malibu Boats, Silo Pharma
Silo rises on deal to jointly develop ketamine-based implant to manage pain
Brief: Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management
Brief: Silo Pharma Announces Positive Results For Novel SPC-15 Treatment
Brief: Silo Pharma And Resyca BV Partner On Device And Cmc Development For Intranasal Ptsd Drug Spc-15
U.S. STOCKS ON THE MOVE-PNC Financial, US homebuilders, Johnson & Johnson
U.S. STOCKS ON THE MOVE-UnitedHealth, EPAM, Datadog
U.S. STOCKS ON THE MOVE-Tesla, UnitedHealth, EPAM Systems
Silo Pharma rises on licensing deal for Alzheimer's drug
Brief: Silo Pharma Secures Exclusive Global License For Alzheimer's Therapeutic